Tempest Therapeutics Reports $27.7 Million Net Loss and Strategic Acquisition in Latest 10-Q Filing

Tempest Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $27.7 million, a substantial increase from the $10.9 million loss reported in the same period last year, marking a 155% rise. This increase in losses was primarily attributed to a $22.2 million expense related to acquired in-process research and development from the recent acquisition of assets from Erigen LLC. Total operating expenses for the quarter reached $27.7 million, compared to $10.9 million in the prior year, reflecting a strategic shift in focus towards advancing its clinical-stage programs.

In terms of revenue, Tempest Therapeutics has not generated any product revenue, consistent with its status as a clinical-stage biotechnology company. The company’s cash and cash equivalents decreased to $1.8 million from $7.7 million at the end of the previous fiscal year, raising concerns about its liquidity and ability to continue operations. The accumulated deficit as of March 31, 2026, stood at $270.1 million, underscoring the financial challenges faced by the company.

Strategically, Tempest completed the acquisition of the Erigen Assets on February 3, 2026, which included several CAR-T cell therapy candidates aimed at treating various cancers. This acquisition was executed through the issuance of 8,268,495 shares of common stock, valued at approximately $19.9 million based on the stock's closing price at the time. The company also entered into a funding commitment with Factor Bioscience Inc. to secure up to $20 million in financial support over the next 18 months, although the company expressed uncertainty regarding its ability to meet the terms of this commitment.

Operationally, Tempest has undergone significant changes, including a reduction in workforce from 26 to 5 employees as part of cost-cutting measures initiated in 2025. The company is actively exploring additional funding options to support its operations, as it anticipates that its current cash reserves will only sustain operations for less than 12 months. The company’s management has indicated that it will continue to focus on advancing its clinical programs while navigating the financial landscape, which remains volatile due to broader economic conditions.

Looking ahead, Tempest Therapeutics aims to leverage its recent acquisitions and funding commitments to enhance its product pipeline and potentially initiate a U.S. registrational study for its lead CAR-T therapy, TPST-2003, later this year. However, the company acknowledges the substantial risks and uncertainties associated with its operational and financial outlook, particularly in light of its ongoing losses and the need for additional capital to sustain its business.